This study deals with the combined therapy of GnRH-agonist (GnRH-a) and HMG for stimulation in 15 patients who failed two prior in vitro fertilization attempts. Fifty-three patients who received HMG without GnRH-agonist suppression served as controls. Comparing the HMG group with GnRH-a/HMG cycles, the cancellation rate dropped from 35.5% to 13.2%. Oocyte recovery was similar in both groups, as were the fertilization rates, 88.4% in GnRH-a and 82% in HMG cycles, respectively. The number of embryos available for transfer was virtually identical in both groups (3.7 vs. 3.6). Embryo cleavage speed was higher in GnRH-a than in HMG regimens. The E2 rise was smooth in the GnRH-a group compared to the sharp rise observed in the HMG group. The pregnancy rate per transfer was 30.5% in the GnRH-a group versus 20.5% in the HMG group. GnRH-a seems to offer a clear improvement to a number of stimulation failures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0020-7292(91)90486-o | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group.
Materials And Methods: This retrospective cohort study involved 165 POR patients aged 18-45 years who underwent IVF between 2018 and 2022.
Functional analysis of SRY variants in individuals with 46,XY differences of sex development.
Mol Cell Endocrinol
January 2025
Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia. Electronic address:
In mammals, male sexual development is initiated by the expression of the Sex-determining-Region-Y (SRY) gene. SRY contains a highly conserved high mobility group (HMG) box essential for DNA binding and activity. Variants in SRY cause Differences of Sex Development (DSD), accounting for 10-15% of 46, XY gonadal dysgenesis cases.
View Article and Find Full Text PDFDjsoxP-1 and Djsox5 are essential for tissue homeostasis and regeneration in Dugesia japonica.
Cell Tissue Res
January 2025
College of Life Science, Henan Normal University, No. 46, Jianshe Road, Xinxiang 453007, Henan, China.
Sox genes encode a family of transcription factors that regulate multiple biological processes during metazoan development, including embryogenesis, tissue homeostasis, nervous system specification, and stem cell maintenance. The planarian Dugesia japonica contains a reservoir of stem cells that grow and divide continuously to support cellular turnover. However, whether SOX proteins retain these conserved functions in planarians remains to be determined.
View Article and Find Full Text PDFFenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats.
Toxicol Rep
June 2025
Endocrinology Laboratory, Department of Zoology, University of Kalyani, West Bengal 741235, India.
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate is a PPAR-α agonist. Piperine is an alkaloid mostly found in black pepper fruits.
View Article and Find Full Text PDFAdjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Article Synopsis
- Early neurological deterioration (END) is linked to poor outcomes in acute ischemic stroke (AIS), and the study investigates how the drug evolocumab can help prevent this condition by lowering LDL cholesterol levels.
- The research was a clinical trial with AIS patients divided into two groups: one receiving evolocumab combined with atorvastatin and the other receiving atorvastatin alone, assessing outcomes like END rates and inflammatory markers over 7 days.
- Results showed that the combination therapy group had significantly lower rates of END (13.2% vs. 24.3%) and a much higher LDL cholesterol target achievement rate (74.3% vs. 14.7%), indicating the effectiveness of evolocumab in this context.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!